Drug interactions
Encorafenib + Netupitant-palonosetron
Severity: Major
Encorafenib and Netupitant-palonosetron: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Netupitant raises encorafenib exposure through CYP3A4 inhibition, increasing the risk of toxicities including QT prolongation. Encorafenib labeling advises avoiding moderate inhibitors or reducing the dose.
What this interaction means in plain words
Encorafenib and Netupitant-palonosetron can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Encorafenib belongs to Oncology; Netupitant-palonosetron belongs to Gastrointestinal Tract.
Why it happens
CYP3A4 inhibition by netupitant decreases encorafenib clearance.
What to do
Use an alternative antiemetic if possible. If unavoidable, reduce encorafenib to the labeled dose and monitor ECG and electrolytes.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Encorafenib and Netupitant-palonosetron, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Netupitant-palonosetron
- Apomorphine + Netupitant-palonosetron Contraindicated
- Flibanserin + Netupitant-palonosetron Contraindicated
- Apalutamide + Netupitant-palonosetron Major
- Avapritinib + Netupitant-palonosetron Major
- Carbamazepine + Netupitant-palonosetron Major
- Cobimetinib + Netupitant-palonosetron Major
Other interactions of Encorafenib
Frequently asked questions
Can I take Encorafenib with Netupitant-palonosetron?
MediHelp rates the interaction as major. Encorafenib and Netupitant-palonosetron can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Netupitant raises encorafenib exposure through CYP3A4 inhibition, increasing the risk of toxicities including QT prolongation. Encorafenib labeling advises avoiding moderate inhibitors or reducing the dose.
How serious is the interaction between Encorafenib and Netupitant-palonosetron?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Use an alternative antiemetic if possible. If unavoidable, reduce encorafenib to the labeled dose and monitor ECG and electrolytes.
What other medicines interact with Netupitant-palonosetron?
MediHelp also lists interactions of Netupitant-palonosetron with, for example, Apomorphine, Flibanserin, Apalutamide. The full list is on the Netupitant-palonosetron page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
